Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-(adenosine tetraphosphate-methyl)-7,8-dihydropterin
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
6-(adenosine tetraphosphate-methyl)-7,8-dihydropterin is an experimental small molecule bisubstrate analogue designed to inhibit the enzyme 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK). HPPK catalyzes a key step in folate biosynthesis by transferring pyrophosphate from ATP to 6-hydroxymethyl-7,8-dihydropterin. This enzyme is essential for microorganisms but absent in humans and animals. The compound consists of a pterin moiety linked via four phosphate groups to an adenosine moiety. It acts as a potent competitive inhibitor of HPPK by occupying both the pterin and ATP binding sites on the enzyme. Its high affinity for HPPK makes it valuable as a tool compound for biochemical studies and as a lead structure for antimicrobial drug development targeting folate biosynthesis in bacteria[1][3][2].
- Other names
- 6-(adenosine tetraphosphate-methyl)-7,8-dihydropterinDB04158DB-04158DB 04158ZINC000098208626ZINC-000098208626ZINC 000098208626
02
Targets
HPPK (6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase)
Beyond the preview
Go deeper on 6-(adenosine tetraphosphate-methyl)-7,8-dihydropterin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6-(adenosine tetraphosphate-methyl)-7,8-dihydropterin.